Emergent Biosolutions Inc (NYSE: EBS) is 16.67% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $13.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EBS stock was last observed hovering at around $2.69 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $2.80, the stock is 9.89% and 27.05% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.27 million and changing 4.09% at the moment leaves the stock -32.30% off its SMA200. EBS registered -72.50% loss for a year compared to 6-month loss of -38.73%. The firm has a 50-day simple moving average (SMA 50) of $0.87 and a 200-day simple moving average (SMA200) of -$1.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 66.67% gain in the last 1 month and extending the period to 3 months gives it a 15.70%, and is -11.67% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.37% over the week and 17.19% over the month.
Emergent Biosolutions Inc (EBS) has around 1600 employees, a market worth around $145.26M and $1.05B in sales. Profit margin for the company is -72.11%. Distance from 52-week low is 97.18% and -79.52% from its 52-week high. The company has generated returns on investments over the last 12 months (-68.24%).
Emergent Biosolutions Inc quarterly earnings per share for the current quarter are estimated at -$0.62 with sales reaching $224.5M over the same period.The EPS is expected to grow by 67.90% this year, but quarterly earnings will post 4.70% year-over-year.
Emergent Biosolutions Inc (EBS) Top Institutional Holders
191 institutions hold shares in Emergent Biosolutions Inc (EBS), with institutional investors hold 82.23% of the company’s shares. The shares outstanding are 52.20M, and float is at 49.77M with Short Float at 23.18%. Institutions hold 79.85% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 9.23 million shares valued at $67.85 million. The investor’s holdings represent 17.82% of the EBS Shares outstanding. As of Jun 29, 2023, the second largest holder is State Street Corporation with 6.79 million shares valued at $49.94 million to account for 13.11% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 4.34 million shares representing 8.38% and valued at over $31.92 million, while Dimensional Fund Advisors LP holds 2.88% of the shares totaling 1.49 million with a market value of $10.95 million.
Emergent Biosolutions Inc (EBS) Insider Activity
The most recent transaction is an insider sale by Zoon Kathryn C,the company’sDirector. SEC filings show that Zoon Kathryn C sold 1,830 shares of the company’s common stock on Jun 02 ’23 at a price of $8.35 per share for a total of $15280.0. Following the sale, the insider now owns 49971.0 shares.
Emergent Biosolutions Inc disclosed in a document filed with the SEC on May 25 ’23 that Zoon Kathryn C (Director) sold a total of 1,700 shares of the company’s common stock. The trade occurred on May 25 ’23 and was made at $8.38 per share for $14246.0. Following the transaction, the insider now directly holds 51801.0 shares of the EBS stock.
